Mission Street have established a market-leading and rapidly growing Science and Innovation platform.
The current portfolio comprises over 1.5 million sq ft of committed projects in key strategic locations within Oxford, Cambridge and Bristol. Our innovative schemes and campuses are being developed speculatively with the first phases being the next available lab space in the respective locations.
Mission Street was founded in 2017 as an independent investor, developer and operator of Science and Innovation real estate. The company has since established itself as an industry leader working in conjunction with a highly experienced Advisory Board who bring invaluable insight and expertise from the perspective of our customers.
The current portfolio comprises over 1.5 million sq ft of committed projects in key strategic locations within Oxford, Cambridge and Bristol. Our innovative schemes and campuses are being developed speculatively with the first phases being the next available lab space in the respective locations.
Mission Street was founded in 2017 as an independent investor, developer and operator of Science and Innovation real estate. The company has since established itself as an industry leader working in conjunction with a highly experienced Advisory Board who bring invaluable insight and expertise from the perspective of our customers.
MISSION Therapeutics was founded in 2011. The company focuses on the biology of the DNA damage response (DDR) processes in cancer, optimising small molecule drugs to exploit synthetic lethality to selectively kill high unmet-need tumour types. Targeting deubiquitylating enzymes (DUBs) involved in regulating the DDR, MISSION has built an extensive proprietary biology and chemistry platform (Ubi-Sphere™) to support its discovery of inhibitors of DUBs. The application of DUB inhibitors extends across several therapeutic areas including neurodegeneration and infectious disease. The company is based at the Babraham Research Campus, Cambridge, UK.
Worried about how to protect your business from cybercrime, including ransomware attacks and theft of confidential business information? Every biomedical and life science company, large or small, is now a target for cyber criminals. Service This is proportionate, affordable, ongoing security, which protects businesses against cybercrime. It starts with an assessment of your cyber risks. Mitigo then take care of the three areas needed to keep your business safe: Technology • On and off site technology assessments • Penetration testing • Vulnerability assessments and vulnerability scanning • Controls and configuration People competence • E-learning • Testing • Simulated phishing Governance • Policies • Cybersecurity handbook • Control and risk management framework • Risk management platform This includes a dedicated expert client Helpdesk & Sandbox to which suspicious content may be sent. Mitigo also provides Emergency cyber breach response, which includes: • Emergency incident response and containment • Forensics and investigation • Assistance on reporting obligations Certifications include: • Cyber Essentials • Cyber Essentials Plus • IASME Governance • ISO 27001 Mitigo is offering One Nucleus members a free cybersecurity assessment to help you understand the areas of your business that are most vulnerable to attack. Listen to The Mitigo Q&A: The Importance of Independent Assurance - https://on.soundcloud.com/r4xQp Find out more about Mitigo’s cybersecurity solution: https://mitigogroup.com/partnership-pages/one-nucleus/ 0209 8191 2053 onenucleus@mitigogroup.com
Mitigo has launched an interactive guide to help you strengthen your cyber security. It debunks myths, shares technical security tips, and teaches you to spot phishing attacks.
Begin your 2025 cyber resolutions – download" target="_blank">https://onenucleus.com/sites/default/files/Mitigo%20Cyber%20Security%20Matters%20One%20Nucleus.pdf">download the guide here.
Mitigo has launched an interactive guide to help you strengthen your cyber security. It debunks myths, shares technical security tips, and teaches you to spot phishing attacks.
Begin your 2025 cyber resolutions – download" target="_blank">https://onenucleus.com/sites/default/files/Mitigo%20Cyber%20Security%20Matters%20One%20Nucleus.pdf">download the guide here.
Drug Discovery
Clinical stage drug development company, bringing a stratified approach to neuroscience drug repurposing using digital biomarkers
No data available
Bespoke relocation service for rentals and purchases, individuals and families. We are highly experienced in corporate relocations. Initial free of charge consultation to discuss your requirements and offer advice. Property search including off market properties, viewings can be carried out on your behalf prior to your arrival, negotiation of the rental or purchase, orientation tour on arrival, settling in services and personalised area guide. We can also search for available school and nursery places and advise you on the most appropriate for your preferences, assisting with the applications. We have a proactive approach with in depth knowledge of the Cambridge property market and an extensive network of local contacts. Move to Cambridge use our expert knowledge of Cambridge and the surrounding area, to find you the best available property in the most suitable location. We offer the complete relocation service from start to finish, providing you with every detail you should need to settle quickly and enjoy your new home and locality.
MSD is a trade name of Merck & Co., Inc., with headquarters in Whitehouse Station, NJ, USA. MSD delivers vaccines, medications, and consumer and animal health products that save and improve the lives of millions around the world. MSD offers therapies for the treatment of cardiovascular disease, high blood pressure, elevated cholesterol levels, diabetes, cancer, benign prostatic hypertrophy, asthma and allergies, arthritis, pain, migraine, glaucoma, osteoporosis, women's health, infectious diseases (antibiotic, antifungal, and antiviral agents) and vaccines to prevent childhood diseases, human papilloma virus, rotavirus, shingles, and hepatitis A, B and C. Worldwide product sales in 2011 were $48 billion.
Mursla is a startup developing a diagnostic device that leverages proprietary nanostructures to significantly improve cancer detection through the utilization of a novel, non-invasive procedure called liquid biopsy.
My Green Lab’s mission is to build a global culture of sustainability in science and is a world leader in developing environmental standards for laboratories and laboratory products—bringing sustainability solutions to the community responsible for the world’s life-changing medical innovations.
The importance of this effort cannot be overlooked - Laboratories are some of the most resource-intensive buildings of any kind. A typical laboratory can use up to 10x more energy and 4x more water than a typical office building. Additionally, laboratory supply chains are responsible for approximately 2% of worldwide plastic waste, making the scientific community’s efforts to reduce its environmental impact a truly global effort. My Green Lab estimates there are over 265,000 labs worldwide and over 2,000,000 laboratory products, each providing an opportunity for My Green Lab programs and services in an increasingly environmentally conscious and cost-sensitive industry.
As such, My Green Lab’s two flagship programs, Green Lab Certification and ACT Label are designed to address the environmental impact in laboratories and lab supply chains respectively. Each certification program delivers customer value by proving frameworks for scientific organizations to reduce environmental impact, realize cost savings, and create market differentiation for their scientific organizations and/or products.
Since the development of the My Green Lab Certification and ACT Label, My Green Lab as an organization has grown from a grassroots effort to the most influential organization in the laboratory sustainability space. My Green Lab counts 23 of 25 of the world’s largest pharma companies as customers, with more than 1,300 labs and 2,400 products certified across 220 organizations and in 39 countries. With proven market fit, its recent endorsement by the United Nations Race to Zero Program, and a substantial lead on the competition, My Green Lab is positioned for global growth.
The importance of this effort cannot be overlooked - Laboratories are some of the most resource-intensive buildings of any kind. A typical laboratory can use up to 10x more energy and 4x more water than a typical office building. Additionally, laboratory supply chains are responsible for approximately 2% of worldwide plastic waste, making the scientific community’s efforts to reduce its environmental impact a truly global effort. My Green Lab estimates there are over 265,000 labs worldwide and over 2,000,000 laboratory products, each providing an opportunity for My Green Lab programs and services in an increasingly environmentally conscious and cost-sensitive industry.
As such, My Green Lab’s two flagship programs, Green Lab Certification and ACT Label are designed to address the environmental impact in laboratories and lab supply chains respectively. Each certification program delivers customer value by proving frameworks for scientific organizations to reduce environmental impact, realize cost savings, and create market differentiation for their scientific organizations and/or products.
Since the development of the My Green Lab Certification and ACT Label, My Green Lab as an organization has grown from a grassroots effort to the most influential organization in the laboratory sustainability space. My Green Lab counts 23 of 25 of the world’s largest pharma companies as customers, with more than 1,300 labs and 2,400 products certified across 220 organizations and in 39 countries. With proven market fit, its recent endorsement by the United Nations Race to Zero Program, and a substantial lead on the competition, My Green Lab is positioned for global growth.